VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.85%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$191M
AUM Growth
-$20.5M
(-9.7%)
Cap. Flow
-$11.9M
Cap. Flow
% of AUM
-6.22%
Top 10 Holdings %
Top 10 Hldgs %
8%
Holding
450
New
8
Increased
100
Reduced
215
Closed
125
Top Buys
| 1 |
Brookfield Infrastructure
BIPC
|
$1.15M |
| 2 |
ECC
Eagle Point Credit Co
ECC
|
$1.05M |
| 3 |
OXLC
Oxford Lane Capital
OXLC
|
$1.03M |
| 4 |
ORAN
Orange
ORAN
|
$395K |
| 5 |
SNP
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
|
$391K |
Top Sells
| 1 |
Delek Logistics
DKL
|
$2.05M |
| 2 |
Western Midstream Partners
WES
|
$788K |
| 3 |
CNXM
CNX Midstream Partners LP
CNXM
|
$744K |
| 4 |
OSB
Norbord Inc.
OSB
|
$657K |
| 5 |
Lamar Advertising Co
LAMR
|
$515K |
Sector Composition
| 1 | Healthcare | 32.34% |
| 2 | Real Estate | 18.02% |
| 3 | Energy | 12.43% |
| 4 | Materials | 10.7% |
| 5 | Financials | 6.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARNA
176
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $376K | 0.2% |
5,034
-673
| -12% | -$50.3K |
|
177
Protagonist Therapeutics
PTGX
$3.77B
| $372K | 0.2% |
19,048
-2,591
| -12% | -$50.6K |
|
|
ALLK
178
DELISTED
Allakos
ALLK
| $371K | 0.19% |
4,551
-608
| -12% | -$49.6K |
|
179
Gladstone Investment Corp
GAIN
$543M
| $371K | 0.19% |
40,784
+4,994
| +14% | +$45.4K |
|
|
BSL
180
Blackstone Senior Floating Rate 2027 Term Fund
BSL
$186M
| $369K | 0.19% |
26,830
-8,346
| -24% | -$115K |
|
181
Brookfield Renewable
BEPC
$5.96B
| $368K | 0.19% |
+9,432
| New | +$368K |
|
|
IGMS
182
DELISTED
IGM Biosciences
IGMS
| $364K | 0.19% |
4,933
-659
| -12% | -$48.6K |
|
183
Compugen
CGEN
$134M
| $360K | 0.19% |
22,149
-3,027
| -12% | -$49.2K |
|
184
SLR Investment Corp
SLRC
$911M
| $355K | 0.19% |
22,374
-4,764
| -18% | -$75.6K |
|
185
Arcutis Biotherapeutics
ARQT
$2.06B
| $354K | 0.19% |
12,081
-1,637
| -12% | -$48K |
|
|
AGEN
186
Agenus
AGEN
$138M
| $353K | 0.19% |
4,500
-613
| -12% | -$48.1K |
|
187
Moderna
MRNA
$9.78B
| $352K | 0.18% |
4,974
-686
| -12% | -$48.5K |
|
188
Iovance Biotherapeutics
IOVA
$901M
| $344K | 0.18% |
10,450
-1,419
| -12% | -$46.7K |
|
|
JRO
189
DELISTED
Nuveen Floating Rate Income Opportunty Fund
JRO
| $344K | 0.18% |
41,957
-13,103
| -24% | -$107K |
|
190
Ascendis Pharma
ASND
$12.5B
| $342K | 0.18% |
2,215
-296
| -12% | -$45.7K |
|
191
Madrigal Pharmaceuticals
MDGL
$9.65B
| $342K | 0.18% |
2,879
-408
| -12% | -$48.5K |
|
192
Quince Therapeutics
QNCX
$86.5M
| $342K | 0.18% |
6,846
-938
| -12% | -$46.9K |
|
|
SWTX
193
DELISTED
SpringWorks Therapeutics
SWTX
| $342K | 0.18% |
7,168
-981
| -12% | -$46.8K |
|
194
Theravance Biopharma
TBPH
$703M
| $342K | 0.18% |
23,148
+1,950
| +9% | +$28.8K |
|
|
NSL
195
DELISTED
NUVEEN SENIOR INCM FD
NSL
| $341K | 0.18% |
70,640
-22,351
| -24% | -$108K |
|
|
EIDX
196
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $341K | 0.18% |
6,745
-924
| -12% | -$46.7K |
|
197
Nuveen Floating Rate Income Fund
JFR
$1.13B
| $340K | 0.18% |
40,925
-14,435
| -26% | -$120K |
|
198
Ovid Therapeutics
OVID
$87.5M
| $337K | 0.18% |
58,716
-8,001
| -12% | -$45.9K |
|
199
Main Street Capital
MAIN
$5.95B
| $336K | 0.18% |
11,375
-2,210
| -16% | -$65.3K |
|
200
Mirum Pharmaceuticals
MIRM
$3.82B
| $336K | 0.18% |
17,458
-2,377
| -12% | -$45.7K |
|